One of our clients was developing an inhalation formulation containing two actives at extremely low concentration. One active was a lypopeptide with no chromophore, the other active was a phosphorothioate oligonucleotide with very unusual properties. The client turned to us after two other CROs failed to develop a viable assay, and thus critical animal studies were significantly delayed. We were able to develop suitable assays in a short timeframe and transfer the methods to the animal facility. Drug development program has since progressed to the clinical stage.